425: TuHURA Biosciences Reports Q1 2025 Financial Results and Provides Corporate Update, Anticipates Phase 3 Trial Initiation

TuHURA Biosciences announced its Q1 2025 financial results and provided a corporate update, highlighting the anticipated initiation of a Phase 3 trial for IFx-Hu2.0 and progress towards acquiring Kineta, Inc.

Summary

• TuHURA Biosciences reported its financial results for the three months ended March 31, 2025.
• The company anticipates initiating a Phase 3 accelerated approval trial of IFx-Hu2.0 as adjunctive therapy with Keytruda for advanced and metastatic Merkel cell carcinoma (MCC) in Q2 2025.
• A Phase 1b/2a trial of IFx-Hu2.0 as adjunctive therapy with pembrolizumab in first-line Merkel cell carcinoma of unknown primary origin (MCCUP) has been initiated.
• TuHURA is targeting to close the acquisition of Kineta, Inc. in Q2 2025 and initiate a Phase 2 trial of Kinetas VISTA inhibiting monoclonal antibody (mAb) in NPM1-mutated acute myeloid leukemia (AML) in Q3 2025.
• Research and development expenses were $4.6 million for the three months ended March 31, 2025, compared to $3.6 million for the same period in 2024.
• General and administrative expenses were $2.4 million for the three months ended March 31, 2025, compared to $1.0 million for the same period in 2024.
• As of March 31, 2025, TuHURAs total shares outstanding was approximately 43.7 million.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with progress in clinical trials and a strategic acquisition. However, the need for additional financing and the presence of a partial clinical hold introduce some uncertainty.

Positives

• The anticipated Phase 3 trial of IFx-Hu2.0 has a Special Protocol Assessment (SPA) agreement with the FDA, potentially saving time and money.
• The Phase 1b/2a trial in MCCUP patients expands the potential patient population for IFx-Hu2.0.
• The acquisition of Kineta, Inc. will add Kinetas VISTA inhibitor antibody, KVA12123, to TuHURAs pipeline.
• TuHURA is developing tumor microenvironment modulators, which could have broad implications for cancer treatment.

Negatives

• The company is working to resolve a manufacturing-related partial clinical hold on the Phase 3 trial of IFx-Hu2.0.
• The closing of the Kineta acquisition is subject to financing and other conditions.
• Increased general and administrative expenses from $1.0 million to $2.4 million for the three months ended March 31, 2025.

Risks

• The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
• The closing of the Kineta acquisition is dependent on securing financing.
• The success of clinical trials is not guaranteed.
• Regulatory approvals are not guaranteed.

Future Outlook

TuHURA anticipates several milestones in the near term, including the initiation of a Phase 3 trial for IFx-Hu2.0, the closing of the Kineta acquisition, and the initiation of a Phase 2 trial for Kinetas VISTA inhibiting mAb. The company also plans to present additional data on its ADC and APC development candidates.

Management Comments

• James Bianco, M.D., President and Chief Executive Officer of TuHURA Biosciences, stated that the company has had an impressive start to 2025 and continues to execute its corporate strategy.
• Dr. Bianco noted that evaluating IFx-Hu2.0 in MCCUP patients is an important component of the overall strategy for the program.
• Dr. Bianco stated that the company is moving towards initiating its Phase 3 accelerated approval trial of IFx-Hu2.0 and anticipates resolving the manufacturing-related partial clinical hold in the coming weeks.
• Dr. Bianco stated that the company is targeting to close the acquisition of Kineta later this quarter and advance KVA12123 into a Phase 2 trial in relapsed or refractory NPM1-mutated AML.
• Dr. Bianco concluded that the company believes that its DOR program has the potential to reprogram the function of MDSCs and M2 macrophages within the tumor microenvironment.

Industry Context

TuHURA is operating in the competitive immuno-oncology space, focusing on overcoming resistance to cancer immunotherapy. The company's focus on tumor microenvironment modulators and combination therapies aligns with current trends in the industry. The acquisition of Kineta provides TuHURA with a valuable asset in the form of a VISTA inhibitor, which is a novel target in immuno-oncology.

Comparison to Industry Standards

• TuHURAs approach of combining IFx-Hu2.0 with Keytruda (pembrolizumab) mirrors strategies employed by companies like Merck, which manufactures Keytruda, to enhance the efficacy of checkpoint inhibitors.
• The development of bi-specific antibody drug conjugates (ADCs) and antibody peptide conjugates (APCs) targeting Myeloid Derived Suppressor Cells (MDSCs) aligns with the industry trend of targeting the tumor microenvironment, similar to efforts by companies like Bristol Myers Squibb and Roche.
• The acquisition of Kineta and its VISTA inhibiting mAb is comparable to other companies acquiring assets to expand their immuno-oncology pipeline, such as Gilead Sciences acquisition of Kite Pharma for its CAR-T therapy.

Management Changes

Stakeholder Impact

• Shareholders may be impacted by the potential dilution from the issuance of shares in connection with the Kineta acquisition.
• Employees may be impacted by the integration of Kineta into TuHURA.
• Patients with Merkel cell carcinoma and acute myeloid leukemia may benefit from the development of new therapies.

Next Steps

• Resolve the manufacturing-related partial clinical hold on the Phase 3 trial of IFx-Hu2.0.
• Initiate the Phase 3 accelerated approval trial of IFx-Hu2.0 in first-line Merkel cell carcinoma.
• Close the acquisition of Kineta, Inc.
• Initiate the Phase 2 trial of Kinetas VISTA inhibiting mAb in NPM1-mutated AML.
• Present non-clinical data on ADC and APC development candidates at relevant medical meetings.

Key Dates

Keywords

TuHURA Biosciences, Kineta, IFx-Hu2.0, VISTA inhibitor, Merkel cell carcinoma, Acute myeloid leukemia, Immuno-oncology, Clinical trial, Acquisition, Financial results